These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 33661300

  • 1. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
    Demers M, Sturtevant S, Guertin KR, Gupta D, Desai K, Vieira BF, Li W, Hicks A, Ismail A, Gonçalves BP, Di Caprio G, Schonbrun E, Hansen S, Musayev FN, Safo MK, Wood DK, Higgins JM, Light DR.
    Blood Adv; 2021 Mar 09; 5(5):1388-1402. PubMed ID: 33661300
    [Abstract] [Full Text] [Related]

  • 2. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR.
    Br J Haematol; 2016 Oct 09; 175(1):141-53. PubMed ID: 27378309
    [Abstract] [Full Text] [Related]

  • 3. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease.
    Nyffenegger N, Zennadi R, Kalleda N, Flace A, Ingoglia G, Buzzi RM, Doucerain C, Buehler PW, Schaer DJ, Dürrenberger F, Manolova V.
    Blood; 2022 Aug 18; 140(7):769-781. PubMed ID: 35714304
    [Abstract] [Full Text] [Related]

  • 4. A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin.
    Levasseur DN, Ryan TM, Reilly MP, McCune SL, Asakura T, Townes TM.
    J Biol Chem; 2004 Jun 25; 279(26):27518-24. PubMed ID: 15084588
    [Abstract] [Full Text] [Related]

  • 5. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
    Ikuta T, Thatte HS, Tang JX, Mukerji I, Knee K, Bridges KR, Wang S, Montero-Huerta P, Joshi RM, Head CA.
    Arch Biochem Biophys; 2011 Jun 01; 510(1):53-61. PubMed ID: 21457702
    [Abstract] [Full Text] [Related]

  • 6. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
    Strader MB, Liang H, Meng F, Harper J, Ostrowski DA, Henry ER, Shet AS, Eaton WA, Thein SL, Alayash AI.
    Bioconjug Chem; 2019 Mar 20; 30(3):568-571. PubMed ID: 30794381
    [Abstract] [Full Text] [Related]

  • 7. Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects.
    Kassa T, Strader MB, Nakagawa A, Zapol WM, Alayash AI.
    Metallomics; 2017 Sep 20; 9(9):1260-1270. PubMed ID: 28770911
    [Abstract] [Full Text] [Related]

  • 8. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.
    Shrestha A, Chi M, Wagner K, Malik A, Korpik J, Drake A, Fulzele K, Guichard S, Malik P.
    Blood Adv; 2021 May 11; 5(9):2385-2390. PubMed ID: 33944896
    [Abstract] [Full Text] [Related]

  • 9. VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
    Abdulmalik O, Pagare PP, Huang B, Xu GG, Ghatge MS, Xu X, Chen Q, Anabaraonye N, Musayev FN, Omar AM, Venitz J, Zhang Y, Safo MK.
    Sci Rep; 2020 Nov 20; 10(1):20277. PubMed ID: 33219275
    [Abstract] [Full Text] [Related]

  • 10. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
    Enakaya NA, Jefferson A, Chew-Martinez D, Matthews JS.
    Acc Chem Res; 2023 Jun 06; 56(11):1279-1286. PubMed ID: 36946781
    [Abstract] [Full Text] [Related]

  • 11. GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model.
    Dufu K, Alt C, Strutt S, Partridge J, Tang T, Siu V, Liao-Zou H, Rademacher P, Williams AT, Muller CR, Geng X, Pochron MP, Dang AN, Cabrales P, Li Z, Oksenberg D, Cathers BE.
    Br J Haematol; 2023 Jul 06; 202(1):173-183. PubMed ID: 36960712
    [Abstract] [Full Text] [Related]

  • 12. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
    Omar AM, Abdulmalik O, Ghatge MS, Muhammad YA, Paredes SD, El-Araby ME, Safo MK.
    Biomolecules; 2020 Nov 02; 10(11):. PubMed ID: 33147875
    [Abstract] [Full Text] [Related]

  • 13. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E, Safo MK, Abdulmalik O, Kato GJ.
    Br J Haematol; 2016 Oct 02; 175(1):24-30. PubMed ID: 27605087
    [Abstract] [Full Text] [Related]

  • 14. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
    Rodgers GP.
    Semin Hematol; 1997 Jul 02; 34(3 Suppl 3):2-7. PubMed ID: 9317195
    [Abstract] [Full Text] [Related]

  • 15. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
    Nakagawa A, Ferrari M, Schleifer G, Cooper MK, Liu C, Yu B, Berra L, Klings ES, Safo RS, Chen Q, Musayev FN, Safo MK, Abdulmalik O, Bloch DB, Zapol WM.
    Mol Pharm; 2018 May 07; 15(5):1954-1963. PubMed ID: 29634905
    [Abstract] [Full Text] [Related]

  • 16. Nitrite decreases sickle hemoglobin polymerization in vitro independently of methemoglobin formation.
    Almeida LEF, Smith ML, Kamimura S, Vogel S, de Souza Batista CM, Quezado ZMN.
    Toxicol Appl Pharmacol; 2023 Aug 15; 473():116606. PubMed ID: 37336294
    [Abstract] [Full Text] [Related]

  • 17. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
    Xu GG, Pagare PP, Ghatge MS, Safo RP, Gazi A, Chen Q, David T, Alabbas AB, Musayev FN, Venitz J, Zhang Y, Safo MK, Abdulmalik O.
    Mol Pharm; 2017 Oct 02; 14(10):3499-3511. PubMed ID: 28858508
    [Abstract] [Full Text] [Related]

  • 18. Quercetin Completely Ameliorates Hypoxia-Reoxygenation-Induced Pathophysiology Severity in NY1DD Transgenic Sickle Mice: Intrinsic Mild Steady State Pathophysiology of the Disease in NY1DD Is Also Reversed.
    Thangaswamy S, Branch CA, Ambadipudi K, Acharya SA.
    Biomolecules; 2021 Oct 06; 11(10):. PubMed ID: 34680105
    [Abstract] [Full Text] [Related]

  • 19. PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.
    Gopalsamy A, Aulabaugh AE, Barakat A, Beaumont KC, Cabral S, Canterbury DP, Casimiro-Garcia A, Chang JS, Chen MZ, Choi C, Dow RL, Fadeyi OO, Feng X, France SP, Howard RM, Janz JM, Jasti J, Jasuja R, Jones LH, King-Ahmad A, Knee KM, Kohrt JT, Limberakis C, Liras S, Martinez CA, McClure KF, Narayanan A, Narula J, Novak JJ, O'Connell TN, Parikh MD, Piotrowski DW, Plotnikova O, Robinson RP, Sahasrabudhe PV, Sharma R, Thuma BA, Vasa D, Wei L, Wenzel AZ, Withka JM, Xiao J, Yayla HG.
    J Med Chem; 2021 Jan 14; 64(1):326-342. PubMed ID: 33356244
    [Abstract] [Full Text] [Related]

  • 20. Potential of isoquercitrin as antisickling agent: a multi-spectroscopic, thermophoresis and molecular modeling approach.
    Syed MM, Doshi PJ, Dhavale DD, Doshi JB, Kate SL, Kulkarni G, Sharma N, Uppuladinne M, Sonavane U, Joshi R, Kulkarni MV.
    J Biomol Struct Dyn; 2020 Jun 14; 38(9):2717-2736. PubMed ID: 31315526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.